source
- Ultragenyx's Angelman gene therapy fails Phase 3, company to cut expensesUltragenyx reported that its late‑stage Aspire trial of apazunersen in Angelman syndrome did not meet its primary or secondary endpoints. The primary goal of improving the Bayley‑4 cognitive raw sc…
- Seattle researchers unveil $95 million AI biology initiative to map nature’s design rulesSeattle scientists have announced a new $95 million effort that uses artificial intelligence to decode the design principles of biological molecules. The project, led by Nobel laureate David Baker,…